Guided by rigorous understanding of biological mechanism of action and rational protein design principles, our programs focus on emerging and challenging disease targets that have the potential to transform the lives of patients.
We are pursuing a balanced portfolio of novel and validated targets in immuno-oncology. Our pipeline leverages synergistic mechanisms of action among innate and adaptive immune cells in the tumor microenvironment.
xCella is discovering and developing highly differentiated therapeutics in other indications.
XC-201: Universal Tumor Targeting
Building on leading scientific work from MIT and Stanford, we created a unique engineered integrin-binding peptide and genetically fused it to an antibody Fc domain.
XC-201 is a “universal” tumor targeting agent that binds a broad panel of integrins (αvβ1, αvβ3, αvβ5, αvβ6, and α5β1 ) expressed at high levels on tumors.
XC-201 has greater specificity to tumors compared to other integrin-binding agents.
XC-201 is peptide-Fc fusion: a “mAb-lite.”
Extensive data elucidating mechanism of action. Efficacy attributed to efficient recruitment of host immune cells to the tumors, rather than through any antagonism of integrin function